Analystreport

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Piper Sandler from $7.50 to $6.00. They now have a "neutral" rating on the stock.

Iovance Biotherapeutics, Inc.  (IOVA) 
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: iovance.com